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Abstract
Background: Back pain is one of the most important causes of functional limitation, disability, and utilization of
health care resources for adults of all ages, but especially among older adults. Despite the high prevalence of back
pain in this population, important questions remain unanswered regarding the comparative effectiveness of
commonly used diagnostic tests and treatments in the elderly. The overall goal of the Back pain Outcomes using
Longitudinal Data (BOLD) project is to establish a rich, sustainable registry to describe the natural history and
evaluate prospectively the effectiveness, safety, and cost-effectiveness of interventions for patients 65 and older with
back pain.
Methods/design: BOLD is enrolling 5,000 patients≥ 65 years old who present to a primary care physician with a
new episode of back pain. We are recruiting study participants from three integrated health systems (Kaiser-
Permanente Northern California, Henry Ford Health System in Detroit and Harvard Vanguard Medical Associates/
Harvard Pilgrim Health Care in Boston). Registry patients complete validated, standardized measures of pain, back
pain-related disability, and health-related quality of life at enrollment and 3, 6 and 12 months later. We also have
available for analysis the clinical and administrative data in the participating health systems’ electronic medical
records. Using registry data, we will conduct an observational cohort study of early imaging compared to no early
imaging among patients with new episodes of back pain. The aims are to: 1) identify predictors of early imaging
and; 2) compare pain, functional outcomes, diagnostic testing and treatment utilization of patients who receive
early imaging versus patients who do not receive early imaging. In terms of predictors, we will examine patient
factors as well as physician factors.
Discussion: By establishing the BOLD registry, we are creating a resource that contains patient-reported outcome
measures as well as electronic medical record data for elderly patients with back pain. The richness of our data will
allow better matching for comparative effectiveness studies than is currently possible with existing datasets. BOLD
will enrich the existing knowledge base regarding back pain in the elderly to help clinicians and patients make
informed, evidence-based decisions regarding their care.
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Background
Back pain is a particularly important problem for older
adults. The prevalence of severe, disabling back pain
increases in older adults [1,2]. Moreover, with an aging
population, the importance of back pain in the U.S. will
only increase in coming decades. Despite this, there is a
paucity of research on back pain in older age, and most
studies to date have been small [1].
The Back pain Outcomes using Longitudinal Data
(BOLD) project establishes a large, community-based
registry of patients aged 65 years and older present-
ing with new episodes of healthcare visits for back
pain. BOLD’s primary aim is to establish an infra-
structure that allows the conduct of prospective, con-
trolled studies comparing the effectiveness of
diagnostic and treatment strategies for back pain in
the elderly. The importance of BOLD stems from the
high prevalence, clinical impact and cost of back
pain, combined with a relative lack of comparative
effectiveness data, especially for older adults. Back
pain, an Institute of Medicine priority condition [3],
is one of the most important causes of functional
limitations and disability among adults in the United
States. Back pain is also one of the most common
reasons for physician visits [4]. The economic impact
of back pain is substantial. Martin et al., estimated
that in 2005, the marginal direct cost of care for
people with back pain compared to those without
was over $86 billion [5].
Although there are numerous guidelines regarding
the diagnosis and treatment of back pain in general,
these evidence-based guidelines do not focus on the
elderly. Age-related differences in the causes of back
pain highlight the need for specific guidelines for
diagnosing and treating back pain in older adults.
For example, back pain due to metastatic cancer has
a higher prevalence in older adults. In a study of pri-
mary care patients with back pain, age older than
50 years was associated with a higher likelihood of
having cancer (positive likelihood ratio = 2.7), al-
though the absolute probability of having cancer
remained small at 1.2% [6]. This increased risk of
cancer, as well the greater prevalence in older adults
of other conditions such as spinal stenosis, vertebral
compression fractures and aortic aneurysms, has led
most guidelines to call for early diagnostic imaging
in the elderly. However, it remains unclear how early
imaging in the elderly affects clinical outcomes and
costs associated with the treatment of back pain. A
primary goal of the BOLD project is to enrich the
existing knowledge base regarding back pain in the
elderly to help clinicians and patients make





The overall goal of this project is to establish a sustain-
able and rich registry to evaluate prospectively the effect-
iveness, safety, and cost-effectiveness of diagnostic
approaches and interventions for elderly patients with
back pain. The registry can also be used to identify and
recruit patients for additional studies. We plan to recruit
5,000 patients age 65 and older with new episodes of
health care visits for back pain (defined as no prior visits
to a health care provider for back pain care within
6 months). Patients who enroll in the registry complete
validated, standardized measures of pain, back pain-
related disability, and health-related quality of life at en-
rollment and 3, 6 and 12 months later. Our project
includes a demonstration comparative effectiveness study
of early (<six weeks after initial medical visit) imaging
versus no early imaging for elderly patients with back
pain. In this observational cohort study we will test the
hypothesis that early imaging is associated with more
interventions and adverse labeling (where simply assign-
ing a diagnostic label results in worse health related
quality of life), greater disability and higher levels of pain
compared to matched controls who do not undergo early
imaging. We will also test the hypothesis that racial and
ethnic minorities will have lower rates of early imaging
than non-minorities. In parallel with construction of the
BOLD registry, we also are performing a double-blind,
randomized controlled trial of epidural steroid with local
anesthetic compared with a local anesthetic injection
alone for spinal stenosis; this component of the study is
described elsewhere [7].
Participating centers
BOLD is recruiting patients at three integrated health
care systems: Kaiser Permanente of Northern California
(KPNC), Henry Ford Health System (HFHS), and Har-
vard Vanguard Medical Associates/Harvard Pilgrim
Health Care (HVMA/HPHC). We chose these sites for
their geographic and demographic diversity. Confining
our registry to the integrated health systems with com-
prehensive electronic medical record systems allows
us to take advantage of the well-defined populations
that their patients comprise as well as the wealth of
data available in these systems, including health care
utilization.
The University of Washington’s Comparative Effective-
ness, Cost and Outcomes Research Center (CECORC)
and Center for Biomedical Statistics (CBS) serve as the
Data Coordinating Center (DCC) for BOLD. A collabor-
ator at Oregon Health and Sciences University (RAD) is
also part of the DCC.
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Institutional review board (IRB) approval
The IRBs at all participating institutions (University of
Washington, Harvard Vanguard, Harvard Pilgrim, Henry
Ford Health System, and Kaiser-Permanente Northern
California) reviewed and approved the protocols for the
BOLD Registry and the Observational Cohort Study of
Early Imaging.
Subject eligibility
We identify patients at their health care visits for back
pain using the Ninth International Classification of Dis-
eases (ICD-9) codes [8]. We recruit subjects from both
primary care clinics and urgent care/emergency care set-
tings. Since our aim is to evaluate treatment effectiveness
(how an intervention performs in the real world) rather
than efficacy (how an intervention performs under ideal
conditions), our inclusion criteria are as broad as pos-
sible. Our inclusion and exclusion criteria are listed in
Table 1.
Patient identification
We screen for study eligibility patients ≥ 65 years old
who have had a primary care visit (including by tele-
phone) or urgent/emergency care visit and been assigned
a diagnosis code indicating back pain within the past
three weeks (Table 2). In addition to patient encounters
with physicians, we also include patients who have had
encounters with non-physician primary care providers
(registered nurses, nurse practitioners and physician
assistants). We select for patients with relatively new
onset episodes of back pain by excluding those with vis-
its for back pain in the previous 6 months.
Patient enrollment
The exact method of the initial subject contact varies
slightly at each site. The site research staff identify and
contact potential subjects by telephone, email, mail or in
person, describing the study and inviting them to partici-
pate using a standardized script. In the invitation we pro-
vide a web address (www.backpainproject.org) that has
additional information about the study.
If the patient agrees, the research staff determines eli-
gibility, verifying inclusion/exclusion criteria that were
assessed during the query of the electronic health infor-
mation system (Table 3). Patients provide verbal assent
for their participation in the registry, which includes ac-
cess to their medical records.
We offer subjects a $10 gift card or check for each
completed interview (baseline and 3, 6, and 12 months
later). The total time for completing the study question-
naires at each assessment is approximately 15–30
minutes.
Data collection
Our data come primarily from two sources: subject ques-
tionnaires and electronic data records. We have
attempted to minimize the questionnaire burden while
still obtaining important information regarding the
patient’s back pain. At baseline, trained research coordi-
nators/interviewers administer the questionnaires either
in person or over the telephone within three weeks of a
subject’s index primary care visit.
Follow-up
We contact each registry patient at three, six and
12 months after baseline to collect data on patient treat-
ments and outcomes. For follow-ups, the questionnaires
are either self-administered by the subject using a mailed
hard copy or administered by a research coordinator
over the telephone. We plan to develop an on-line ver-
sion of the questionnaire as an option for subjects to
complete after being sent a link by email.
Follow-up questionnaires can be completed within a
two-week window on either side of the follow-up time-
point. We use a computerized tracking system to identify
when patients enter the interview window and when
interviews are complete. If patients withdraw from the
study, we attempt to identify the reason.
Baseline and follow-up measures
We collect demographic information and information
regarding back pain duration and back pain recovery
expectations at baseline. We also administer the follow-
ing measures at each assessment: 1) Roland-Morris
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
1. Age≥ 65 years
2. Primary care visit for back pain based on ICD9 code (Table 2)
Exclusion criteria:
1. Health care encounter for back pain within 6 months
2. Previously contacted for registry participation
3. Prior lumbar spine surgery
4. Developmental spine deformities
5. Inflammatory spondyloarthropathy
6. Spinal malignancy or infection
7. History of cancer within past 5 years excluding
non-melanomatous skin cancer
8. History of HIV within past 5 years
9. No telephone
10. Planning on leaving Health System within the next
12 months
11. Unable to understand English
12. Severe mental impairment that would interfere with
answering questions
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Table 2 ICD9 Inclusion and Exclusion Codes for the Registry/Observational Cohort
Inclusion Diagnoses Exclusion Diagnoses
ICD9 Code Description ICD9 Code Description
307.89 Psychogenic backache V66.7 Encounter for palliative care
721.3 Lumbosacral spondylosis w/o myelopathy 042, 079.53 HIV within the last five years
140-239.9 (except 173, 210–229) Cancer other than non-melanoma skin





721.6 Ankylosing vertebral hyperostosis 324.1 Intraspinal abscess
721.7 Traumatic spondylopathy 331.0 Alzheimer’s disease
721.8 Other allied disorders of spine 630–676 Pregnancy-related diagnoses
721.9 Spondylosis of unspecified site w/o myelopathy 720.0–720.9 Inflammatory spondyloarthropathies
721.90 Spondylosis of unspecified site w/o myelopathy 730–730.99 Osteomyelitis
722.1 Displacement of thoracic or lumbar disc w/o myelopathy 737.30–737.39 737.40–737.43 Developmental spine deformities
722.10 Displacement of lumbar disc w/o myelopathy 733.8, 733.81–733.8InternalRef>) Non-union/mal-union of fracture
722.11 Displacement of thoracic disc w/o myelopathy 805–806.9 Fractures of spinal column
722.2 Degeneration of intervertebral disc, site unspecified 839–839.59 All vertebral dislocations
722.3 Schmorl’s nodes E800-E849.9 Vehicular accidents
722.31 Schmorl’s nodes- thoracic region 03.09; 80.50 Prior lumbar surgery:
722.32 Schmorl’s nodes- lumbar region 80.51; 80.52; •Laminectomy
722.5 Degeneration of thoracic or lumbar intervertebral disc 80.59; 81.00; •Discectomy
722.51 Degeneration of thoracic or thoracolumbar intervertebral disc 81.06–81.09; •Fusion
722.52 Degeneration of lumbar or lumbosacral intervertebral disc 03.02; 03.6; •Other
722.6 Degeneration of intervertebral disc, site unspecified 78.69
722.9 Other and unspecified disc disorder
722.90 Other and unspecified disc disorder of unspecified region
722.92 Other and unspecified disc disorder of thoracic region
722.93 Other and unspecified of lumbar region
724 Other and unspecified disorders of back
724.0 Spinal stenosis, not cervical
724.00 Spinal stenosis of unspecified region
724.01 Spinal stenosis- thoracic
724.02 Spinal stenosis- lumbar
724.03 Spinal stenosis- lumbar with neurogenic claudication
724.09 Spinal stenosis- other region
724.1 Pain in thoracic spine
724.2 Lumbago
724.3 Sciatica
724.4 Back pain w/radiation, unspec
724.5 Backache, unspecified
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Disability Questionnaire (RMDQ) [9], modified slightly
to indicate disability due to back or leg pain (sciatica); 2)
0–10 numerical rating scales (NRS) of average back and
leg pain in past 7 days; 3) Brief Pain Inventory activity
interference scale; [10,11] 4) Patient Health Question-
naire (PHQ)-4 Depression and Anxiety screen; [12] 5)
the EuroQol-5D (EQ5D) [13] 6) Behavioral Risk Factor
Surveillance System (BRFSS) survey (2 questions about
falls) [14]. We repeat the same measures at each follow-
up time-point except for the duration of pain and patient
recovery expectation questions.
Baseline descriptive measures
Pain Duration: We ask subjects at baseline to categorize
the length of the current episode of back or leg pain (sci-
atica) as follows: 1) less than 1 month; 2) 1–3 months, 3)
3–6 months; 4) 6–12 months; 5) 1–5 years; and 6) more
than 5 years.
Patient Expectations: We ask subjects to use a 0–10
NRS to rate their confidence that their pain will be com-
pletely gone or much better in 3 months.
Primary outcome measure
Roland-Morris Disability Questionnaire: Our primary
outcome measure is the Roland-Morris Disability Ques-
tionnaire (RMDQ) [9], a back pain-specific functional
status questionnaire adapted from the generic Sickness
Impact Profile (SIP) [15]. The original version consists of
24 yes/no items, which represent common dysfunctions
in daily activities experienced by patients with back pain
[9] .We use a slightly modified version of the question-
naire in which we add “or leg (sciatica)” to the words
“back pain” where appropriate. A single score is derived
by summing the items endorsed by the respondent, with
higher scores indicating worse function. Both the original
and modified RMDQ have proven to be more responsive
to change over time than most subscales of the SF-36
[16] or disability day questions from national health sur-
veys [16]. Its internal consistency is excellent [17]. Its
Table 2 ICD9 Inclusion and Exclusion Codes for the Registry/Observational Cohort (Continued)
733.95 Stress fracture of other bone
738.4 Acquired spondylolisthesis
738.5 Other acquired deformity of back or spine
739.2 Nonallopathic lesions- thoracic, not elsewhere classified
739.3 Nonallopathic lesions, lumbar, not elsewhere classified




846.1 Sacroiliac (ligament) sprain
846.2 Sacrospinatus (ligament) sprain
846.3 Sacrotuberous (ligament) sprain
846.8 Other specified sites of sacroiliac region sprain




847.9 Sprain- unspecified site of back
Table 3 Additional Exclusion Criteria Assessed at Initial
Telephone Contact
1. Previously contacted for registry participation
2. Severe cognitive impairment that would interfere with answering
questions
3. Tumor/cancer related to the spine




7. Spine deformity from childhood
8. Spine fracture
9. Vehicular accident as cause of back pain
10. Prior lumbar spine surgery
11. No telephone, or planning to leave health system within
next 12 months
12. Unable to understand English
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construct validity is supported by significant associations
in the expected directions with symptom severity, neuro-
logic deficits, opioid medication use, work absenteeism,
and other measures of health status (subscales of the
SF-36, disability days) [18,19]. The RMDQ was the meas-
ure most responsive to clinical changes over time in the
Maine Low Back Pain Cohort study [16].
Additional patient-reported measures
Pain Numerical Rating Scale (NRS): We ask subjects to
rate separately their average back and leg pain within the
past seven days on 0–10 scales, with 0 = no pain and
10 =worst pain imaginable. Investigators commonly use
NRS’s of pain intensity as outcomes in clinical trials of
pain therapies, and these ratings have been demonstrated
to be valid, reliable, and sensitive to detecting change in
pain intensity after treatment [20]. The Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) recommended a 0–10 NRS measure
of pain intensity as a core outcome measure in pain clin-
ical trials and noted that NRS measures had advantages
over visual analogue scale (VAS) measures, including
ability to be administered by telephone, preference by
patients, and less missing and incomplete data [21]. Fur-
ther, older adults may have difficulty completing VAS
measures [20]. The IMMPACT group also recommended
that clinical trials report the percentage of patients
obtaining reductions in pain intensity from baseline of at
least 30% on the NRS, and suggested that investigators
may also wish to report the percentages of patients
obtaining reductions in pain intensity of at least 50%.
We plan to use both of these indicators of clinically
meaningful change.
Pain Interference The validated Brief Pain Inventory
(BPI) Interference scale measures pain interference with
activities [11].The scale consists of 7 ratings (0–10) of
how much back pain interferes with the following: gen-
eral activity, mood, ability to walk, normal work, rela-
tions with other people, sleep and enjoyment of life.
Patient Health Questionnaire-4 Depression and Anxiety
Screen The PHQ-4 is a four-item screen for depression
and anxiety that has good sensitivity and specificity for
identifying depression and anxiety disorders [22].
EQ-5D The EQ-5D is a standardized health outcome in-
strument consisting of five dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression). In
addition, the instrument includes a “feeling thermometer”
to assess respondents’ current health-related quality of life
(0–100). The EQ-5D has been extensively validated and
studied for a wide variety of conditions and populations,
including the elderly, and is used as a utility measure in
cost-effectiveness analyses (www.euroquol.com) [23].
Behavioral Risk Factor Surveillance System (BRFSS)
Falls The BRFSS Falls screen is a two-item questionnaire
that assesses the number of falls the respondent has had
in the past 3 weeks and how many resulted in injury
[24-29].
Additional data
In addition to the patient-reported outcome measures,
we will use electronic medical record and administrative
data that are available at these integrated health systems.
These health systems have standardized administrative
and clinical data collected across their systems
(Figure 1). We will generate queries of each health sys-
tem’s information system to acquire demographic,
pharmacy, laboratory, vital sign, and provider data.
Table 4 contains a list of variables that we plan provi-
sionally to obtain from each site for each subject.
Data management
For all interviews, research coordinators enter data on
specially formatted, paper data collection forms that are
stored securely at each site. In addition, sites have the
option of entering data directly into the on-line REDCap
data system [30]. This has the added advantage of auto-
mated range and logic checks that reduce data entry
errors. The study has two classes of data: 1) data con-
taining protected health information (PHI) that is only
stored locally at each site on a secure server; and 2) a
limited data set with dates of service but no other PHI
that is uploaded to a central database at the DCC using
a web interface.
Research assistants check data from the interviews for
missing or unclear responses while the subject is still
available. The data coordinating center’s senior program-
mer directs the data management and re-checks the data
for quality. We defined specific logic rules for establish-
ing the internal consistency of responses across several
variables. When necessary, we check the original data
collection forms or re-contact the subject.
Analytic approach
In many registries, there may be a relatively small sub-
group of interest (e.g., a treatment or diagnostic testing
prevalence of 1 or 2%) and a large number of controls
available for a comparative analysis of outcomes. As a
general analytic approach in BOLD, we will evaluate
cases in comparative studies using 3:1 matched controls
with the nearest propensity score [31].
Propensity-based matching is a strategy for assembling
similar groups of patients in the absence of randomization.
We will use this method to select control patients who are
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similar to patients who have selectively received the inter-
vention of interest (e.g. early imaging). If we do not
appropriately match controls on important baseline char-
acteristics to patients who receive the intervention, there
is a risk of obtaining biased results when comparing cases
with controls due to confounding [31-37]. Propensity
score matching aims to provide a valid estimate of the
intervention effect by comparing patients who have and
have not had the intervention and who also have similar
observed characteristics.
For a given research question and set of patients, we will
use logistic regression models (or multi-level logistic regres-
sion models for ordinal or multilevel treatments; e.g., levels
of treatment dose) to generate a propensity score for each
person, using variables that are significant predictors of the
intervention of interest. We will then match the propensity
score of each case who received the intervention to the
nearest propensity scores (up to 3) available among control
patients whose propensity scores lie within a caliper win-
dow of 0.2σ of the case index, where σ is a measure of vari-
ation in the propensity score distributions of cases and
controls as given in Rosenbaum and Rubin [35]. If no con-
trol propensity scores fall within the caliper window of a
particular index case, then the index case will be excluded
from any analyses.
Observational cohort of early imaging
We will conduct an observational cohort study of early
imaging in seniors with new visits for back pain as our
first comparative study using data from the BOLD regis-
try. Our goal is to test the hypothesis that imaging of the
lumbar spine within 6 weeks of the index visit (early im-
aging) is associated with worse patient outcomes and
increased health care utilization and costs. Patients who
get early imaging may be those with the worst pain or
most alarming clinical presentation. However, given the
variability in clinician ordering patterns, there is also a
reasonable likelihood that those patients who do and do
not get early imaging have considerable overlap.
Prior work has suggested an association between early
imaging and subsequent interventions [38,39] but lacked
the statistical power to detect a significant association.
Subject eligibility
All subjects enrolled in the registry will be eligible for
the observational study of early imaging. Cases selected
for the observational cohort will be registry patients who
had early imaging of the lumbar spine. We will identify
propensity score-matched controls from the registry (see
below) who did not have early imaging of their spine.
Analytic approach to the observational cohort of early
imaging
Our overall aim for the observational cohort study is to
compare the pain, function, and resource utilization and
associated costs of patients who have early (within six
weeks of index medical visit) imaging (radiographs, mag-
netic resonance imaging (MRI), computed tomography
Figure 1 Virtual Data Warehouse data elements.
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(CT) and bone scans) to those who do not have early im-
aging. The sample will consist of registry patients with
new episodes of back pain. Our primary hypothesis is
that patients who undergo early imaging will have worse
modified RMDQ scores at one year compared with those
who do not receive early imaging, after controlling for
baseline back pain-related disability, pain severity and
pain duration. Our rationale is that imaging may lead to
adverse labeling [40] or more interventions (injections,
surgery) [39], with resultant complications. We will also
test the hypothesis that early-imaged subjects undergo
more invasive and more resource-intensive subsequent
interventions than those who do not.
Matching
We will construct a propensity score based upon the
logit function of the probability of receiving early im-
aging (e.g., the log odds) for a patient with specific char-
acteristics or prognostic factors [37]. We will use fixed
matching of age (5-year strata), sex (male/female), and
race (Caucasian/African American/other) in the gener-
ation of the propensity score and include candidate base-
line covariates such as other co-morbidities or diagnoses
identified at baseline, modified RMDQ score, and pain
intensity rating. Patients receiving early imaging will be
matched to the closest control whose propensity score
differed by less than 0.2σ among those patients within
five years of age.
Primary analysis
Our primary outcome measure is back-specific disability
measured by the RMDQ at 12 months. We have selected
the 12-month assessment as the primary outcome be-
cause this allows adequate time for any intervention
benefit to manifest, and is the final assessment opportun-
ity for the initial registry study design.
We will first assess comparability of baseline character-
istics between the matched groups to gauge the effective-
ness of the propensity matching and then address any
residual covariate imbalances through model adjustment.
Rosenbaum and Rubin suggested that an approach com-
bining both the propensity score and covariate adjust-
ment is superior to the use of either strategy alone [41].
Using the propensity-matched pairs, we plan to use a
paired t-test to compare the between-group 12-month
change in RMDQ. In conjunction with this primary ana-
lysis, we will use multivariate linear regression models
adjusting for the propensity score and baseline factors
that appear to have residual imbalance in order to com-
pare groups with and without early imaging.
We will use multivariate linear regression models
adjusting for the propensity score or conditional logistic
models to identify predictors of patient outcome at the
one-year follow-up. We will use interaction terms be-
tween the early imaging and baseline characteristics to
identify variables that predict differences in the outcome
associations between the two groups.
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that we will subsequently
categorize relatedness to back pain)
PROCEDURES
Date Date
Generic name CPT code
Brand name Indication for procedure
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Amount Performing physician specialty
Specialty of treating physician
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Specialty Care Charlson score
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We will include subjects who have subsequent imaging
more than six weeks after entry to the study in the non-
early imaging group. We will compare characteristics of
subjects who receive later imaging to those who do not
in a sensitivity analysis.
Secondary analyses
We will conduct similar analyses for the RMDQ at three
and six months as well as for the pain NRS and EQ-5D
using all data through one year. We will use methods ap-
propriate for the analysis of repeated measures such as
linear mixed models or repeated measures ANCOVA
[42], adjusting for the propensity score. We will assess
binary secondary outcomes such as achievement of a
30% reduction in pain using conditional logistic regres-
sion models.
Using the patient-reported data and the electronic
health system information systems, we will enumerate
the number and type of invasive interventions that
patients undergo following enrollment. These interven-
tions are listed in Table 5. We will use fixed effects con-
ditional Poisson regression models to compare adjusted
spinal surgery rates between those patients who did or
did not receive early imaging, conditional on matched
pair [43]. In addition, we will examine the time to first
invasive intervention using survival analysis with a Cox
proportional hazards model and adjust for the propensity
score for early imaging.
Another hypothesis is that racial and ethnic minorities
will have lower rates of early imaging than non-minorities.
To test this hypothesis, we will use the registry to compare
rates of early imaging between African Americans/ Blacks
and Whites as well as between Hispanics and Whites. We
will test for differences in rates using fixed effects condi-
tional Poisson regression models, controlling for the pro-
pensity score and residual imbalances among important
covariates. We will also examine subsequent invasive inter-
ventions as well as outcomes in each of these ethnic and
racial subgroups. If early imaging rates are indeed lower in
racial and ethnic minorities, we would expect subsequent
invasive interventions to be fewer and functional status
better.
Economic analysis
The primary economic hypothesis is that patients receiving
early imaging will have higher health care utilization,
higher costs, and worse outcomes at one year compared to
those not receiving early imaging. The primary economic
outcome will be one-year incremental cost per quality-
adjusted life year (QALY) gained from the private/public
payer perspective [44].
The cost-effectiveness assessment will use the health
systems’ electronic medical records and administrative
data as well as patient-reported outcome data. We will
use the electronic data to assess within-health system
categories of resource utilization (e.g., office visits, proce-
dures, surgeries, tests, medications). We will use the
MarketscanW data warehouse (http://marketscan.thom-
sonreuters.com/marketscanportal/) to obtain an estimate
of 2012 private payer average unit costs for medications
and medical procedures/services.
We will report short-term costs and consequences
(baseline to 3 months) and assess six-month and one-
year outcomes incorporating the linear mixed-model ap-
proach used in the primary outcomes analysis. Sensitivity
and specific scenario analyses will be undertaken to
evaluate uncertainty on cost-effectiveness parameters
[45].
Sample size
Prior studies suggest that approximately 15%–30% of
back pain patients will have early imaging of the lumbar
spine [46]. Given a registry size of 5,000 subjects, we ex-
pect 750–1,500 patients in the BOLD registry will have
early imaging and comprise cases for the observational
matched cohort study.
In a matched study, missing data at follow-up in either
the case or matched control imply that neither patient’s
data will be included in a matched analysis. That is, if we
anticipate between 10–15% loss to follow-up equally
balanced between comparison groups, the number of
missing data points can be as much as doubled in any
matched or conditional analysis. To compensate for this,
we will enrich the control sample with 3:1 matched sam-
pling so that each case will have up to three controls fol-
lowed in an identical manner. In Table 6, we see that
this number of patients offers adequate power to detect
minimally clinically relevant differences in functional and
pain outcomes, as well as important differences in rates
of surgery, complications, or adverse events. Given that
one of our enrolling sites (Kaiser Permanente Northern
California) is much larger than the other sites, we antici-
pate approximately triple the number of subjects to be
Table 5 Invasive Interventions
Diagnostic Therapeutic- Percutaneous Therapeutic- Open
Surgical
1. Myelography 1. Epidural
steroid injections
1. X-stop
2. Arthrography 2. Facet injection 2. Laminectomy/
discectomy/
decompression
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enrolled from KPNC than the other two sites, or 3,000
vs. 1,000 subjects.
An important advantage of a registry is the ability to
detect relatively rare events due to the large sample size.
We base our sample size estimates on the ability to de-
tect and make inference on relatively rare events. In the
primary care setting, examples of rare events would be
subsequent surgery or adverse outcomes from interven-
tions such as epidural steroid injections. While our first
planned use of the registry is for the comparative effect-
iveness evaluation of early imaging vs. no-early imaging
in the elderly, we envision other evaluations such as the
comparative effectiveness of physical therapy vs. no
physical therapy.
Data access
As the registry progresses in size and maturity, we antici-
pate making the BOLD resources available to researchers
interested in evaluating diagnostic tests, treatments, and
outcomes among elderly patients with back pain.




In the U.S., many spine-related registries are device- or
procedure-focused and hence recruit patients primarily
from specialists. Outside the U.S., several prospective
spine registries/cohorts have been established to study
various aspects of back pain and while somewhat
broader in scope, most still have a specialist focus
[48-50]. In contrast, Costa and colleagues established an
inception cohort of 973 primary care patients with acute
(less than two weeks) low back pain [51], demonstrating
both the feasibility and value of such an approach. Iden-
tifying patients early in the course allowed measurement
of baseline factors that predicted progression and
chronicity.
The Back Complaints in the Elders (BACE) consortium
is an international group of investigators who have inde-
pendently established prospective cohorts in a primary
care setting to investigate back pain among seniors [52].
Investigators from the Netherlands, Australia and Brazil
are collaborating to identify prognostic indicators leading
to the transition from acute to chronic back pain in
the elderly. The objectives of BOLD parallel those of
BACE and similar study structures facilitate international
comparisons.
Strengths of registries
A great advantage of registries is that patient enrollment
is easier than intervention trials, so large sample sizes
are feasible. This increases generalizability and the ability
to detect rare events, such as complications.
Limitations of registries
Roovers highlighted the limitations of registries, includ-
ing lack of proper control groups, confounding, bias,
poor data quality control, and potential conflicts of inter-
est due to industry sponsorship [53]. Due to these limita-
tions, registries will never replace randomized controlled
trials (RCTs). The most important limitation of registries
in general is the lack of a pre-defined control group.
However, we can identify important subgroups contained
within the registry to use for comparative effectiveness
evaluations, such as patients with and without early im-
aging, and use propensity-matched controls to minimize
selection bias associated with treatment or diagnostic
testing.
Table 6 BOLD Power Estimates (registry size = 5,000
patients)*
Index Case Prevalence
2% 3% 5% 10%
Number of Cases 100 150 250 500
Effect Size (D)
RDQ†
1.5 - - 61% 88%
2.0 - 63% 84% 98%
2.5 65% 82% 96% 99%
Pain NRS†
0.7 - 52% 74% 96%
1.0 65% 82% 96% 99%
1.3 87% 96% 99% 99%
Incremental Cost per QALY Gain< $50,000††
$500 / 0.03 DQALY - - - 38%
$500 / 0.06 DQALY 45% 61% 82% 98%
$800 / 0.03 DQALY - - - 21%
$800 / 0.06 DQALY 36% 51% 72% 95%
Rare Events (Surgery, Complication, or Binary Event Rate)**
2% Incidence Rate
RR = 1.5 - - - -
RR = 2.0 - - - 62%
RR= 2.5 - - 60% 88%
5% Incidence Rate
RR = 1.5 - - - 51%
RR= 2.0 - 51% 73% 95%
RR= 2.5 - 79% 95% 99%
*Comparisons where power estimates are below 50% are not provided
† Conservatively assumes 1:1 case:control ratio, SD estimates of 7.5 and 3.0 for
RDQ and Pain NRS respectively.
†† Conservatively assumes 1:1 case to control ratio, calculated for one-year
time period, cost standard deviations of $4,000 per group, QALY standard
deviations of 0.2 per group based on EQ-5D and 6-month effect improvement,
and a positive correlation of 0.3 between costs and changes in EQ-5D [47].
Assuming a negative correlation did not affect power substantially.
**Assumes 3:1 matching of controls to index cases.
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Another limitation of registries is selection bias asso-
ciated with enrollment. Physicians might be more likely to
enroll uncomplicated patients who are likely to have better
outcomes. We avoid this shortcoming by using the health
information systems to identify potential patients and have
a research coordinator contact and enroll them (without
prior screening by the primary care physician). Limiting
enrollment to integrated health systems somewhat limits
generalizability, since the delivery of care within these sys-
tems is distinct from the fee-for-service delivery system,
with unique incentives. Nevertheless, we believe that the
advantages of integrated health systems (comprehensive
tracking of healthcare utilization and well-defined popula-
tion) far outweigh the limitations.
Diagnostic imaging and back pain in the elderly
Patients and clinicians both tend to under-appreciate
the disadvantages of diagnostic testing. The degree of
potential controversy associated with this issue was
recently emphasized by the release of the U.S. Pre-
ventative Health Services Task Force report on mam-
mography [54]. The panel recommended against
screening women in the 40–49 year old age group
due to the high rate of false positives that could lead
to unnecessary further testing and invasive procedures
resulting in morbidity without benefit. In addition,
these false positives could lead to anxiety and poorer
health-related quality of life. Spine imaging in the eld-
erly has similar problems. The rate of incidental find-
ings is high, as high as 90% for some findings [55].
These findings can lead to adverse labeling as well as
increased unnecessary interventions, with associated
morbidity [40]. Most guidelines exclude patients older
than 50 or 65 years from imaging constraints because
of the increased prevalence of serious conditions in
the elderly. However, it is in the elderly that the rate
of incidental lumbar imaging findings is highest [55].
One of our goals is to examine the consequences of
early imaging in the elderly by comparing elderly
patients who receive early imaging to those who do
not.
The BOLD registry establishes an infrastructure for
studying back pain in the elderly and performing future
comparative effectiveness and cost-effectiveness evalua-
tions. Strengths include accessing patients from a com-
munity-based setting and using integrated health plans
to facilitate the tracking of resource use. Since the aims
and design parallel studies by an international consor-
tium of investigators, comparison with cohorts from the
Netherlands, Australia and Brazil will be possible. Even
without the potential for future collaborations with inter-
national collaborators, the BOLD registry is a valuable
new resource for comparative effectiveness research in
the United States.
Competing interests
Dr. Jarvik has the following potential conflicts of interest, although they do
not relate directly to the subject of this manuscript, he lists them in the spirit
of full disclosure. He serves on the Comparative Effectiveness Advisory Board
for GE Healthcare. He is a co-founder and stockholder of PhysioSonics, a high
intensity focused ultrasound company, and receives royalties for intellectual
property. He is also a consultant for HealthHelp, a radiology benefits
management company.
Acknowledgements
The study is supported by the Agency for Healthcare Research and Quality :
(AHRQ) R01 HS019222.
Author details
1Department of Radiology, University of Washington, Seattle, WA, USA.
2Department of Neurological Surgery, University of Washington, Seattle, WA,
USA. 3Comparative Effectiveness, Cost and Outcomes Research Center,
University of Washington, Seattle, WA, USA. 4Department of Anesthesiology,
Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston,
MA, USA. 5Neuroscience Institute, Henry Ford Hospital, Detroit, MI, USA.
6Division of Research, Kaiser Permanente Northern California, Oakland, CA,
USA. 7Department of Health Services, University of Washington, Seattle, WA,
USA. 8Department of Pharmacy, University of Washington, Seattle, WA, USA.
9Departments of Family Medicine and Internal Medicine, Oregon Health
Sciences University, Portland, OR, USA.
Authors’ contributions
JGJ, BAC, ALA, BWB, RAD, JLF, PH, LK, SSN, DRN, SDS and JAT developed the
original concept of the study and developed the design of BOLD Registry
study. ZB and KJ participated in the design of as BOLD and are coordinators.
All authors have read and approved the final version of the article.
Received: 12 March 2012 Accepted: 3 May 2012
Published: 3 May 2012
References
1. Docking RE, Fleming J, Brayne C, Zhao J, Macfarlane GJ, Jones GT:
Epidemiology of back pain in older adults: prevalence and risk factors
for back pain onset. Rheumatology (Oxford) 2011, 50(9):1645–1653.
2. Dionne CE, Dunn KM, Croft PR: Does back pain prevalence really decrease
with increasing age? A systematic review. Age Ageing 2006, 35(3):229–234.
3. Initial National Priorities for Comparative Effectiveness Research: In.
Washington DC: Institute of Medicine; 2009.
4. Schappert SM, Rechtsteiner EA: Ambulatory medical care utilization
estimates for 2006. Natl Health Stat Report 2008, 8:1–29.
5. Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, Hollingworth W,
Sullivan SD: Expenditures and health status among adults with back and
neck problems. JAMA 2008, 299(6):656–664.
6. Deyo RA, Diehl AK: Cancer as a cause of back pain: frequency, clinical
presentation, and diagnostic strategies. J Gen Intern Med 1988, 3:230–238.
7. Friedly J, Bresnahan BW, Comstock B, Turner JA, Deyo RA, Sullivan SD,
Heagerty P, Bauer Z, Nedeljkovic SS, Avins AL, et al: Study Protocol- Lumbar
Epidural Steroid Injections for Spinal Stenosis (LESS): a double-blind
randomized controlled trial of epidural steroid injections for lumbar
spinal stenosis among older adults. BMC Musculoskelet Disord 2012,
13(1):48.
8. International Classification of Diseases, 9th Revision, 5th Edition, Clinical
Modification. Los Angeles, Calif: Practice Management Information Corp;
1993.
9. Roland M, Morris R: A study of the natural history of back pain. Part 1:
Development of a reliable and sensitive measure of disability in low
back pain. Spine 1983, 8:141–144.
10. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC:
Dimensions of the impact of cancer pain in a four country sample: new
information from multidimensional scaling. Pain 1996, 67(2–3):267–273.
11. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994, 23(2):129–138.
12. Kroenke K, Spitzer RL, Williams JB, Lowe B: An ultra-brief screening scale
for anxiety and depression: the PHQ-4. Psychosomatics 2009,
50(6):613–621.
Jarvik et al. BMC Musculoskeletal Disorders 2012, 13:64 Page 11 of 12
http://www.biomedcentral.com/1471-2474/13/64
13. Brooks R: EuroQOL: the current state of play. Health Policy 1996,
37(1):53–72.
14. Centers for Disease Control and Prevention: Self-reported falls and fall-
related injuries among persons aged > or =65 years–United States,
2006. MMWR Morb Mortal Wkly Rep 2008, 57(9):225–229.
15. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The Sickness Impact Profile:
Development and final revision of a health status measure. Med Care
1981, 19:787–805.
16. Patrick DL, Deyo RA, Atlas SJ, Singer DE, Chapin A, Keller RB: Assessing
health-related quality of life in patients with sciatica. Spine 1995, 20
(17):1899–1908.
17. Patrick DL, Deyo RA: Generic and disease-specific mesures in assessing
health status and quality of life. Med Care 1989, 27(suppl):S217–S232.
18. Deyo RA, Andersson G, Bombardier C, Cherkin DC, Keller RB, Lee CK, Liang
MH, Lipscomb B, Shekelle P, Spratt KF, et al: Outcome measures for
studying patients with low back pain. Spine 1994,
19(18 Suppl):2032S–2036S.
19. Deyo RA, Diehr P, Patrick DL: Reproducibility and responsiveness of health
status measures. Statistics and strategies for evaluation. Control Clin Trials
1991, 12(4 Suppl):142S–158S.
20. Jensen M, Karoly P: Self-report scales and procedures for assessing pain in
adults. In Handbook of Pain Assessment Second ed. New York: The Guilford
Press; 2001:15–34.
21. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP,
Kerns RD, Stucki G, Allen RR, Bellamy N, et al: Core outcome measures for
chronic pain clinical trials: IMMPACT recommendations. Pain 2005,
113(1–2):9–19.
22. Kroenke K, Spitzer RL, Williams JB: The Patient Health Questionnaire-2:
validity of a two-item depression screener. Med Care 2003,
41(11):1284–1292.
23. Barton GR, Sach TH, Avery AJ, Jenkinson C, Doherty M, Whynes DK, Muir KR:
A comparison of the performance of the EQ-5D and SF-6D for
individuals aged> or = 45 years. Health Econ 2008, 17(7):815–832.
24. Buchner DM, Hornbrook MC, Kutner NG, Tinetti ME, Ory MG, Mulrow CD,
Schechtman KB, Gerety MB, Fiatarone MA, Wolf SL, et al: Development of
the common data base for the FICSIT trials. J Am Geriatr Soc 1993, 41
(3):297–308.
25. Ganz DA, Higashi T, Rubenstein LZ: Monitoring falls in cohort studies of
community-dwelling older people: effect of the recall interval. J Am
Geriatr Soc 2005, 53(12):2190–2194.
26. Hannan MT, Gagnon MM, Aneja J, Jones RN, Cupples LA, Lipsitz LA,
Samelson EJ, Leveille SG, Kiel DP: Optimizing the tracking of falls in
studies of older participants: comparison of quarterly telephone recall
with monthly falls calendars in the MOBILIZE Boston Study. Am J
Epidemiol 2010, 171(9):1031–1036.
27. Mackenzie L, Byles J, D’Este C: Validation of self-reported fall events in
intervention studies. Clin Rehabil 2006, 20(4):331–339.
28. Pluijm SM, Smit JH, Tromp EA, Stel VS, Deeg DJ, Bouter LM, Lips P: A risk
profile for identifying community-dwelling elderly with a high risk of
recurrent falling: results of a 3-year prospective study. Osteoporos Int
2006, 17(3):417–425.
29. Tinetti ME, Baker DI, McAvay G, Claus EB, Garrett P, Gottschalk M, Koch ML,
Trainor K, Horwitz RI: A multifactorial intervention to reduce the risk of
falling among elderly people living in the community. N Engl J Med 1994,
331(13):821–827.
30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research
electronic data capture (REDCap)–a metadata-driven methodology and
workflow process for providing translational research informatics
support. J Biomed Inform 2009, 42(2):377–381.
31. Rosenbaum P, Rubin DB: The central role of the propensity score in
observational studies for causal effects. Biometrika 1983, 70:41–55.
32. Dehejia RH, Wahba S: Propensity score-matching methods for
nonexperimental causal studies. Rev Econ Stat 2002, 84(1):151–161.
33. Pearl J: Causality: Models, Reasoning and Inference. Cambridge: Cambridge
University Press; 2000.
34. Rosenbaum PR: Design of observational studies. 1st edition. New York:
Springer; 2009.
35. Rosenbaum PR, Rubin DB: The bias due to incomplete matching.
Biometrics 1985, 41(1):103–116.
36. Rowan KM, Welch CA, North E, Harrison DA: Drotrecogin alfa (activated):
real-life use and outcomes for the UK. Crit Care 2008, 12(2):R58.
37. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ:
Analysis of observational studies in the presence of treatment selection
bias: effects of invasive cardiac management on AMI survival using
propensity score and instrumental variable methods. JAMA 2007, 297
(3):278–285.
38. Jarvik JG, Hollingworth W, Martin B, Emerson SS, Gray DT, Overman S,
Robinson D, Staiger T, Wessbecher F, Sullivan SD, et al: Rapid magnetic
resonance imaging vs radiographs for patients with low back pain: a
randomized controlled trial. JAMA 2003, 289(21):2810–2818.
39. Webster BS, Cifuentes M: Relationship of early magnetic resonance
imaging for work-related acute low back pain with disability and medical
utilization outcomes. J Occup Environ Med 2010, 52(9):900–907.
40. Modic MT, Obuchowski NA, Ross JS, Brant-Zawadzki MN, Grooff PN,
Mazanec DJ, Benzel EC: Acute low back pain and radiculopathy: MR
imaging findings and their prognostic role and effect on outcome.
Radiology 2005, 237(2):597–604.
41. Rosenbaum PR, Rubin DB: Constructing a Control Group Using
Multivariate Matched Sampling Methods That Incorporate the Propensity
Score. Am Stat 1985, 39(1):33–38.
42. Diggle PJ, Heagerty P, Zeger SL: Analysis of longitudinal data. Oxford: Oxford
University Press; 1993.
43. Cummings P, McKnight B: Analysis of matched cohort data. Stata J 2004,
4:274–281.
44. Drummond MF, O’Brien B, Stoddart GL, Torrance GW: Methods for the
economic evaluatio of health care programmes. 2nd edition. Oxford: Oxford
University Press; 1997.
45. Briggs A, Claxton K, Sculpher M: Decision modeling for health economic
evaluation. Oxford: Oxford University Press; 2008.
46. Graves JM, Fulton-Kehoe D, Martin DP, Jarvik JG, Franklin GM: Factors
Associated with Early MRI Utilization for Acute Occupational Low Back
Pain: A Population-Based Study from Washington State workers
compensation. Spine (Phila Pa 1976) 2011. doi:10.1097/
BRS.0b013e31823a03cc.
47. Glick HA, Doshi JA, Sonnad SS, Polsky D: Economic evaluation in clinical trials.
Oxford: Oxford University Press; 2007.
48. Melloh M, Staub L, Aghayev E, Zweig T, Barz T, Theis JC, Chavanne A, Grob
D, Aebi M, Roeder C: The international spine registry SPINE TANGO: status
quo and first results. Eur Spine J 2008, 17(9):1201–1209.
49. Stromqvist B, Fritzell P, Hagg O, Jonsson B: The Swedish Spine Register:
development, design and utility. Eur Spine J 2009, 18(Suppl 3):294–304.
50. Schluessmann E, Diel P, Aghayev E, Zweig T, Moulin P, Roder C: SWISSspine:
a nationwide registry for health technology assessment of lumbar disc
prostheses. Eur Spine J 2009, 18(6):851–861.
51. Costa Lda C, Maher CG, McAuley JH, Hancock MJ, Herbert RD, Refshauge
KM, Henschke N: Prognosis for patients with chronic low back pain:
inception cohort study. BMJ 2009, 339:b3829.
52. Scheele J, Luijsterburg PA, Ferreira ML, Maher CG, Pereira L, Peul WC, van
Tulder MW, Bohnen AM, Berger MY, Bierma-Zeinstra SM, et al: Back
complaints in the elders (BACE); design of cohort studies in primary care:
an international consortium. BMC Musculoskelet Disord 2010, 12:193.
53. Roovers JP: Registries: what level of evidence do they provide? Int
Urogynecol J Pelvic Floor Dysfunct 2007, 18(10):1119–1120.
54. U.S. Preventive Services Task Force: Screening for breast cancer: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med 2009, 151(10):716–726. W-236.
55. Jarvik JJ, Hollingworth W, Heagerty P, Haynor DR, Deyo RA: The
Longitudinal Assessment of Imaging and Disability of the Back
(LAIDBack) Study: baseline data. Spine 2001, 26(10):1158–1166.
doi:10.1186/1471-2474-13-64
Cite this article as: Jarvik et al.: Study protocol: The back pain outcomes
using longitudinal data (BOLD) registry. BMC Musculoskeletal Disorders
2012 13:64.
Jarvik et al. BMC Musculoskeletal Disorders 2012, 13:64 Page 12 of 12
http://www.biomedcentral.com/1471-2474/13/64
